3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
2
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
41
Lung Neoplasms
15
Neoplasms
2
NSCLC
2
Breast Neoplasms
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Sexual Dysfunction, Physiological
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Small Cell Lung Cancer With EGFR Mutation
1
Non Small Cell Lung Cancer Metastatic
1
NSCLC Patients With Brain Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma
1
Meningeal Carcinomatosis
1
Lung Cancer Metastatic
1
Locally Advanced or Metastatic Non-squamous NSCLC
1
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
1
Lethal Congenital Contracture Syndrome 2
1
Head and Neck Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Advanced Solid Tumors
1
Adenocarcinoma of Lung
1
Interventions
Bevacizumab
76
Fluorouracil
56
Cetuximab
47
Leucovorin
44
Oxaliplatin
43
pembrolizumab
35
Irinotecan
34
Folfox protocol
24
Capecitabine
24
HMPL-013
22
Specimen Handling
18
trifluridine tipiracil drug combination
16
Nivolumab
15
Blood Specimen Collection
15
Panitumumab
14
regorafenib
13
Magnetic Resonance Spectroscopy
13
Trifluridine
12
Standard of Care
12
Gemcitabine
12
Biopsy
12
Cisplatin
11
sintilimab
10
Interviews as Topic
10
IFL protocol
10
Drug Therapy
10
Carboplatin
9
tislelizumab
8
Trastuzumab
8
Cyclophosphamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colorectal Neoplasms
×
osimertinib
×
Clear all
NCT05647122
2026-05-11
EGRET
AstraZeneca
Phase 1
Recruiting
403 enrolled